

## Nate Gray

Associate

---

ngray@cooley.com

+1 415 693 2442

San Francisco

Venture Capital  
Emerging Companies  
Mergers and Acquisitions  
Capital Markets  
Artificial Intelligence  
Life Sciences and Healthcare  
Biotechnology  
Medtech  
Digital Health  
Climate Tech

---

Nate focuses on representing emerging and growth-stage life sciences and tech companies throughout their life cycles – including corporate formation, venture capital, growth equity and cross-over financings, corporate spinouts, mergers and acquisitions and initial public offerings. His life sciences experience spans a range of biopharmaceutical technologies, tools, diagnostics, digital health and medical device technologies. He also represents private equity firms, venture capital firms and angel investors in investment transactions and portfolio company-related matters.

Nate is passionate about working with companies that are developing technological and scientific innovations that will transform industries and improve lives. He is a dedicated, responsive counselor and advocate for his clients, and seeks to be a long-term partner in the growth and success of his clients' businesses.

During law school, he was an Edward F. Hennessey Distinguished Scholar, a Paul J. Liacos scholar and an editor for the Boston University Law Review.

## Representative matters

Nate's representative transactions include advising:

- Alamar Biosciences in its \$128 million Series C financing, \$80 million Series B financing and spinout of Attovia Therapeutics\*
- BillionToOne in its initial public offering, \$130 million Series D financing, \$125 million Series C financing, \$48.5 million equity and \$35 million debt financing\*
- RevenueCat in its \$50 million Series C financing and acquisition of Dipsea\*
- Monarch Tractor, an electric tractor company, in its \$133 million Series C financing\*
- Leitmotif in various climate tech investments\*
- TeneoTwo in its sale to AstraZeneca for up to \$1.27 billion\*
- Miroculus, a microfluidics company, in its sale to INTEGRA Biosciences\*
- A Fortune 500 biopharmaceutical company in its \$30 million private investment in public equity (PIPE) investment in Gritstone bio in connection with a collaboration, license and option agreement to research and develop a vaccine-based immunotherapy treatment for HIV\*
- A Fortune 500 biopharmaceutical company in its exclusive option to acquire Tizona Therapeutics,

consisting of the acquisition by the company of a 49.9% equity interest in Tizona for \$300 million, an option for the company to acquire the remaining equity interests of Tizona for \$100 million, and up to \$1.25 billion of potential future milestone payments to Tizona equity holders\*

- A Fortune 500 biopharmaceutical company in its exclusive option to acquire Pionyr Immunotherapeutics, consisting of the acquisition by the company of a 49.9% equity interest in Pionyr for \$275 million, an option for the company to acquire the remaining equity interests of Pionyr for \$315 million, and up to \$1.15 billion of potential future milestone payments to Pionyr equity holders\*

\* Representation handled before joining Cooley.

## Education

Boston University School of Law JD, magna cum laude, 2016

Kenyon College BA, cum laude, 2010

## Admissions & Credentials

California

## Memberships & Affiliations

Protect Our Winters